Literature DB >> 1428799

Veralipride-induced tardive dystonia in a patient with bipolar psychosis.

A S Gabellini1, A Pezzoli, P De Massis, T Sacquegna.   

Abstract

Veralipride is a benzamide derivative effective in the treatment of menopausal syndrome. Despite its antidopaminergic action, extrapyramidal side effects seem to be very uncommon. We observed a patient with bipolar psychosis, who developed segmental dystonia after taking the drug. The disorder slowly receded in 14 months, but reappeared during neuroleptic therapy a few months later. To the best of our knowledge, this is the first case of veralipride-induced tardive dystonia, and the affective disorder might have predisposed our patient to the development of this tardive side effect.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1428799     DOI: 10.1007/bf02233409

Source DB:  PubMed          Journal:  Ital J Neurol Sci        ISSN: 0392-0461


  6 in total

1.  Depression as a risk factor in tardive dyskinesia.

Authors:  M Rush; F Diamond; M Alpert
Journal:  Biol Psychiatry       Date:  1982-03       Impact factor: 13.382

2.  [Dyskinesias due to veralipride].

Authors:  D Laplane; M Dougados; J M Macron
Journal:  Nouv Presse Med       Date:  1982-06-05

3.  Tardive dyskinesia--reversible and persistent.

Authors:  D V Jeste; S G Potkin; S Sinha; S Feder; R J Wyatt
Journal:  Arch Gen Psychiatry       Date:  1979-05

4.  Tardive dystonia: late-onset and persistent dystonia caused by antipsychotic drugs.

Authors:  R E Burke; S Fahn; J Jankovic; C D Marsden; A E Lang; S Gollomp; J Ilson
Journal:  Neurology       Date:  1982-12       Impact factor: 9.910

5.  High dosage anticholinergic therapy in dystonia.

Authors:  S Fahn
Journal:  Neurology       Date:  1983-10       Impact factor: 9.910

6.  Sulpiride-induced tardive dystonia.

Authors:  L G Miller; J Jankovic
Journal:  Mov Disord       Date:  1990       Impact factor: 10.338

  6 in total
  1 in total

Review 1.  Drug-induced movement disorders.

Authors:  F J Jiménez-Jiménez; P J García-Ruiz; J A Molina
Journal:  Drug Saf       Date:  1997-03       Impact factor: 5.606

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.